Study title: A 6-Week, Double-Blind, Placebo-Controlled, Parallel-Group Randomized-Withdrawel Study to Evaluate the Continued Efficacy of Modafinil at Dosages Up to 425 mg/day in Patients with Attention-Defizit/Hyperactivity Disorder who are Resonders to Modafinil Treatment, Followed by a 12-month Open-Label Extension Period.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Nervous System Diseases | |||||
| Brands: | |||||
| MAH holders: | |||||
| Assessment: | |||||
| Active substance: MODAFINIL | |||||
| ATC code: | |||||
| Document link: EUdraCT_reduced_datafields_for_Interim_publication-Modafinil.xls | |||||
| Document date: 2011-09-19 | |||||
| Study number: C1538/3048/AD/US | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |